You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News and reporting on breast cancer.
The recently renamed company will use the project to develop a new version of its next-generation sequencing assay for cancer mutational analysis.
This is the fifth neratinib approval for Puma's licensing partner STA, which is also commercializing the drug in Australia, New Zealand, Singapore, and Brunei.
An analysis of societal and health system cost-effectiveness and outcomes points to the benefits of expanding pathogenic BRCA1/2 variant testing in six countries.
The analysis suggested survival and other benefits for breast cancer patients with BRCA1/2 mutations who were aware of their germline risk before diagnosis.
Analyzing both circulating tumor DNA and circulating tumor cells, investigators could classify patients into groups with significantly higher and lower recurrence risk.
The open-label, multi-center trial will start enrolling patients in the third quarter to evaluate the safety of lasofoxifene combined with abemaciclib.
The Quantum Leap-sponsored I-SPY 2 trial will evaluate Byondis' antibody-drug conjugate SYD985 against standard of care for HER2-low, early-stage breast cancer.
Enhertu, or trastuzumab deruxtecan, will also receive accelerated assessment by the European Medicines Agency's Committee for Medicinal Products for Human Use.
In the Phase III ASCENT trial, antibody-drug conjugate Trodelvy was able to improve clinical outcomes in patients with relapsed or refractory metastatic TNBC who received at least two therapies prior.
A Myriad Genetics-funded team found that an 86-SNV polygenic score could modify breast cancer risk in women with pathogenic mutations in cancer risk genes.